 This is an open label phase I clinical trial with two arms, representing single and fractionated radiation therapy Figure 4.1. Within each arm the radiation dose is pre-determined and not escalated. Panobinostat will be administered orally 3 times a week for 2 weeks. Panobinostat will be dose-escalated independently in each arm. There is no intra-patient dose escalation. 